| abstract |
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours post-primary treatment: a) a first therapeutic agent effective against cancer stem cells, such as a cytotoxic chemotherapy; and b) a second therapeutic agent that disrupts a downstream effect of a tissue repair signalling cascade induced by the primary treatment, including an inhibitor of neu- 1 sialidase such as oseltamivir phosphate, or an inhibitor of at least one cytokine associated with stem cell enrichment such as HGF, IL-6, TGF-beta, PGE-2 or PDGF-BB. There is also provided a cancer treatment with chemotherapy agent, such as a checkpoint inhibitor, in combination with either a neuraminidase 1 inhibitor such as oseltamivir phosphate, or a COX-2 inhibitor such as celecoxib, or both. |